Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCombined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs
Journal of Cancer Research & Clinical Oncology, 06/23/09
Zahorowska B et al. - In a review of epidermal growth factor receptor (EGFR)-targeted monotherapy and combination treatment with other drugs, it appears that research conducted into mechanisms of action and synergy of these combination treatments is likely to enhance the role of the EGFR target in future cancer treatment.
Methods- Targeted therapy refers to anticancer treatment which specifically targets key molecules of cancer cells and/or neovascular cells, aiming to interfere with processes of tumorigenesis, cancer progression, and metastasis.
- EGFR was the first receptor to be proposed for targeted cancer therapy, having been found to be commonly overexpressed in a range of solid tumors and play a role in cancer cell proliferation, apoptosis, angiogenesis, invasion, and metastasis.
- Despite successful development of EGFR-targeted pharmacological agents, clinical and molecular studies have indicated several limitations to the broad application of this treatment as a monotherapy.
- Novel combination treatments, which might optimize the effect of EGFR inhibition have been investigated.
- Research conducted into the mechanisms of action and synergy of these combination treatments is likely to enhance the role of the EGFR target in future cancer treatment.
Related Articles
A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis
Rheumatology, 11/20/09
Relevance Score: 69%%
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
British Journal of Haematology, 11/20/09
Relevance Score: 68%%
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Cancer Chemotherapy and Pharmacology, 11/18/09
Relevance Score: 68%%
Compliance With the Treatment of Hypertension: The Potential of Combination Therapy
The Journal of Clinical Hypertension, 11/11/09
Relevance Score: 68%%
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Relevance Score: 68%%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer
Journal of Clinical Oncology, 12/01/09
Results of a phase II study of bortezomib in patients with relapsed or refractory indolent lymphoma
Blood, 12/01/09
Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin ; An evaluation of the therapeutic index with special emphasis on cardiac toxicity
Chemotherapy, 12/01/09
Sponsor
Article Search
Sponsor
Sponsor